SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

UroToday's exclusive Video Lecture content covering Advanced Prostate Cancer.

Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial. July 18, 2025 Unplanned hospitalization among advanced prostate cancer patients by diabetes status-a ...

WCET 2024 optimizing stone treatment, Michelle Jo Semins, laser modalities, world’s first ureteroscopy and laser lithotripsy, MOSES technology.

Extended Outcomes of Intravesical Valrubicin and Docetaxel as Secondary Salvage Treatment for Recalcitrant High-risk Non-muscle-invasive Bladder Cancer - Expert Commentary July 18, 2025 Traditional ...

Clear explanation of what a "Foley" or indwelling catheter is, the 2 types of insertions, their use cases, and the risk of CAUTI if catheterization isn't properly managed.

ASCO GU 2024, CheckMate 214 trial, nivolumab, ipilimumab, nivolumab plus ipilimumab, renal cell carcinoma (RCC), checkpoint inhibitor combination therapy.

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and molecular imaging session and a presentation by Dr. Jiarou Wang discussing the first human study of 68 Ga-P17-079 in ...

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.

PSMA and Beyond PSMA-targeted prostate biopsy, MRI-guided biopsy, PIRADS 2 lesion, 68Ga-PSMA-11, PSMA guided fusion biopsy, PIRADS delineation, SUVmax and PRIMARY score.

ASCO 2025, prostate cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), XALute Study, Xaluritamig, Cabazitaxel, Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy ...